WHO Classification of Tumours: evolution of a global resource in the molecular era

Jennelle C Hodge¹, George J Netto², Bharat Rekhi³, Wendy A Cooper⁴, Michael Eden⁵, Andrew S Field⁶, Vicky Goh⁷, James G Kench⁸, Joseph D Khoury⁹, Katia R M Leite¹⁰, Zhiyong Liang¹¹, Daichi Maeda¹², Miguel Reyes-Múgica¹³, Brian Rous¹⁴, Aleš Ryška¹⁵, Shahin Sayed¹⁶, Antonia Sepulveda¹⁷, Chanjuan Shi¹⁸, Gary Tse¹⁹, Peter Schirmacher²⁰, Dilani Lokuhetty²¹

Affiliations

¹ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
² Department of Pathology and Laboratory Medicine, Pearlman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pathology, Homi Bhabha National Institute University, Parel, Mumbai, Maharashtra, India.
⁴ Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia.
⁵ Histopathology Department, Addenbrooke's Hospital, Cambridge, UK.
⁶ University of NSW Sydney and Notre Dame University, Sydney and St Vincent's Hospital, Sydney, NSW, Australia.
⁷ Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
⁸ Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
⁹ Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.
¹⁰ Department of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
¹¹ Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
¹² Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
¹³ University of Miami Miller School of Medicine, Miami, FL, USA.
¹⁴ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
¹⁵ The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
¹⁶ Department of Pathology, Aga Khan University Hospital Nairobi, Nairobi, Kenya.
¹⁷ Department of Pathology, George Washington University, Washington DC, USA.
¹⁸ Department of Pathology, Duke University Medical Center, Durham, NC, USA.
¹⁹ Department of Anatomical and Cellular Pathology The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
²⁰ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
²¹ International Agency for Research on Cancer and WHO, Evidence Synthesis and Classification Branch, Lyon, France. Electronic address: samarawickremad@iarc.who.int.

PMID: 40179904
DOI: 10.1016/S1470-2045(24)00709-5

WHO Classification of Tumours: evolution of a global resource in the molecular era

Jennelle C Hodge et al. Lancet Oncol. 2025 Apr.

. 2025 Apr;26(4):410-413.

doi: 10.1016/S1470-2045(24)00709-5.

Authors

Affiliations

¹ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
² Department of Pathology and Laboratory Medicine, Pearlman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pathology, Homi Bhabha National Institute University, Parel, Mumbai, Maharashtra, India.
⁴ Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia.
⁵ Histopathology Department, Addenbrooke's Hospital, Cambridge, UK.
⁶ University of NSW Sydney and Notre Dame University, Sydney and St Vincent's Hospital, Sydney, NSW, Australia.
⁷ Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
⁸ Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
⁹ Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.
¹⁰ Department of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
¹¹ Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
¹² Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
¹³ University of Miami Miller School of Medicine, Miami, FL, USA.
¹⁴ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
¹⁵ The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
¹⁶ Department of Pathology, Aga Khan University Hospital Nairobi, Nairobi, Kenya.
¹⁷ Department of Pathology, George Washington University, Washington DC, USA.
¹⁸ Department of Pathology, Duke University Medical Center, Durham, NC, USA.
¹⁹ Department of Anatomical and Cellular Pathology The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
²⁰ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
²¹ International Agency for Research on Cancer and WHO, Evidence Synthesis and Classification Branch, Lyon, France. Electronic address: samarawickremad@iarc.who.int.

PMID: 40179904
DOI: 10.1016/S1470-2045(24)00709-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

WAC has received support for travel to attend meetings from AstraZeneca. BR has received support for travel and accommodation to attend meetings from International Agency for Research on Cancer (IARC), Union for International Cancer Control, and American Joint Committee on Cancer. AR has recevied payment for participation at advisory board meetings for Amgen, AstraZeneca, BMS, EliLilly, Gilead, Merck, MSD, Roche, and Sanofi; as invited speaker for Amgen, Bayer, and BMS; and has received travel support from EliLilly, Gilead, Sanofi–Gilead, and Sanofi. All other authors declare no competing interests. The content of this Comment represents the personal views of the authors and does not represent the views of the authors’ employers and associated institutions. Where authors are identified as personnel of IARC or WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of IARC or WHO. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Copyright © 2025 World Health Organization. Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

WHO Classification of Tumours: evolution of a global resource in the molecular era

Affiliations

WHO Classification of Tumours: evolution of a global resource in the molecular era

Authors

Affiliations

Conflict of interest statement

Grants and funding

LinkOut - more resources

Full Text Sources